| scholarly article | Q13442814 |
| P2093 | author name string | van der Woude FJ | |
| van Es LA | |||
| Wiik A | |||
| The TH | |||
| Permin H | |||
| Rasmussen N | |||
| van der Giessen M | |||
| van der Hem GK | |||
| Lobatto S | |||
| P2860 | cites work | The effect of cyclophosphamide on leukocyte kinetics and susceptibility to infection in patients with wegener's granulomatosis | Q69591364 |
| A non competitive enzyme immunoassay of human lactoferrin in biological fluids | Q70255637 | ||
| Relapses in Wegener's granulomatosis: the role of infection | Q71354293 | ||
| Abnormal reticuloendothelial function in patients with active vasculitis and idiopathic membranous glomerulopathy. A study with 99mTc-labeled heat-damaged autologous red blood cells | Q71705760 | ||
| Granulocyte-specific antinuclear factors in synovial fluids and sera from patients with rheumatoid arthritis | Q33569152 | ||
| The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations | Q34049019 | ||
| The Detection of Granulocyte Alloantibodies with an Indirect Immunofluorescence Test | Q40795932 | ||
| ELISA assays for IgM and IgG rheumatoid factors | Q53758911 | ||
| Circulating immunoglobulin complexes in Wegener's granulomatosis | Q67517839 | ||
| An ultrastructural study of the pathogenesis of tissue injury in limited Wegener's granulomatosis | Q67827842 | ||
| P433 | issue | 8426 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | autoantibody | Q785022 |
| diagnosis | Q16644043 | ||
| P304 | page(s) | 425-9 | |
| P577 | publication date | 1985-02-23 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis | |
| P478 | volume | 1 |
| Q93028522 | A Case of Granulomatosis with Polyangiitis Diagnosed at Autopsy |
| Q28383733 | A case of infection-associated antiproteinase-3-negative cytoplasmic antineutrophil cytoplasmic antibody pauci-immune focal necrotizing glomerulonephritis |
| Q67245008 | A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease |
| Q72963500 | A novel specificity of anticytoplasmic autoantibodies directed against eosinophil peroxidase |
| Q71756207 | A prospective study of antineutrophil cytoplasmic antibody (c-ANCA) and clinical criteria in diagnosing Wegener's granulomatosis |
| Q37225876 | A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies |
| Q28079094 | A role for auto-immunity in chronic rhinosinusitis? Lessons learned from sub-epidermal bullous disorders of the skin |
| Q39626126 | ACP Broadsheet No 143: January 1994. Detection of autoantibodies to neutrophil cytoplasmic antigens |
| Q40868442 | ANCA and associated diseases: immunodiagnostic and pathogenetic aspects |
| Q37811375 | ANCA in the diagnosis of neutrophil-mediated inflammation |
| Q33884806 | ANCA negative pauci-immune glomerulonephritis with systemic involvement |
| Q38062452 | ANCA testing: the current stage and perspectives |
| Q43690505 | ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis |
| Q39210329 | ANCA-Associated Vasculitis Pathogenesis: A Commentary |
| Q38016180 | ANCA-associated renal disease |
| Q30248761 | ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients |
| Q46458557 | ANCA-negative pauci-immune renal vasculitis: histology and outcome |
| Q62573899 | ANCA-negative subglottische Kehlkopf-Stenose im Kindesalter |
| Q43091594 | ANCAs are also antimonocyte cytoplasmic autoantibodies |
| Q56795336 | ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES AS MARKERS FOR SYSTEMIC AUTOIMMUNE DISEASE |
| Q73332851 | Actin is a target antigen of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune hepatitis type-1 |
| Q52055219 | Activated CD4+ and CD8+ T-cell subsets in Wegener's granulomatosis. |
| Q72769493 | Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo |
| Q71993240 | Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis: a predominant role for the IgG3 subclass of ANCA |
| Q72792624 | Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process |
| Q67574217 | Activation of normal neutrophils by anti-neutrophil cytoplasm antibodies |
| Q71270675 | Acute tubulointerstitial nephritis and uveitis with antineutrophil cytoplasmic antibody |
| Q72171796 | Aggravation of rat nephrotoxic serum nephritis by anti-myeloperoxidase antibodies |
| Q72220422 | Alpha 1-antitrypsin deficiency and anti-proteinase 3 antibodies in anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis |
| Q72791717 | Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis |
| Q70616885 | Alpha-enolase: a novel cytosolic autoantigen in ANCA positive vasculitis |
| Q27486163 | An audit of ANCA in routine clinical practice |
| Q34523216 | An unusual cause for fever of unknown origin in a patient with a prosthetic valve |
| Q32035240 | Analysis of anti-neutrophil cytoplasmic antibodies (ANCA): frequency and specificity in a sample of 191 homozygous (PiZZ) alpha1-antitrypsin-deficient subjects |
| Q36901867 | Anca: A Class of Vasculitis-Associated Autoantibodies Against Myeloid Granule Proteins: Clinical and Laboratory Aspects and Possible Pathogenetic Implications |
| Q27473541 | Animal models in ANCA-vasculitis |
| Q80531376 | Anti-MPO small-vessel vasculitis causing prostatis and nephritis |
| Q27490357 | Anti-Neutrophil Cytoplasmic Antibody Pathogenesis in Small-Vessel Vasculitis |
| Q57079501 | Anti-PR-3 antibodies induce endothelial IL-8 release |
| Q42219970 | Anti-PR3 and anti-MPO antibodies are not present in sera of patients with pulmonary tuberculosis |
| Q34228439 | Anti-centromere antibodies (ACA). |
| Q33235127 | Anti-granulocyte antibodies (C-ANCA, P-ANCA, GS-ANA) studied by confocal scanning laser fluorescence microscopy, ELISA, and chemiluminescence techniques |
| Q43692392 | Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis |
| Q34376222 | Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease. |
| Q81128351 | Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates |
| Q27473446 | Anti-myeloperoxidase antibodies in systemic vasculitis |
| Q68255560 | Anti-myeloperoxidase antibodies: Immunological characteristics and clinical associations |
| Q67503399 | Anti-myeloperoxidase autoantibodies in patients with necrotizing glomerular and alveolar capillaritis |
| Q43787629 | Anti-myeloperoxidase autoantibodies react with native but not denatured myeloperoxidase |
| Q70462060 | Anti-neutrophil antibodies in chronic hepatitis and the effect of alpha-interferon therapy |
| Q72108746 | Anti-neutrophil antibodies in chronic viral hepatitis |
| Q72580337 | Anti-neutrophil cytoplasm antibodies (ANCA) in rheumatoid arthritis: relationship to HLA-DR phenotypes, rheumatoid factor, anti-nuclear antibodies and disease severity |
| Q24683141 | Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme |
| Q27473544 | Anti-neutrophil cytoplasm antibodies in rheumatoid arthritis |
| Q44903161 | Anti-neutrophil cytoplasm antibodies, anti-GBM antibodies and anti-dsDNA antibodies in glomerulonephritis |
| Q47984582 | Anti-neutrophil cytoplasm autoantibodies (ANCA). The need for specific and sensitive assays |
| Q36974296 | Anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomerulonephritis. |
| Q67601170 | Anti-neutrophil cytoplasmic antibodies |
| Q78197160 | Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease |
| Q40702326 | Anti-neutrophil cytoplasmic antibodies (ANCA) and inflammatory bowel diseases in Chinese |
| Q45077280 | Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates |
| Q42282783 | Anti-neutrophil cytoplasmic antibodies (ANCA) in myelodysplasia and other haematological disorders |
| Q71614221 | Anti-neutrophil cytoplasmic antibodies (ANCA) in sera from patients with inflammatory bowel disease (IBD). Relation to disease pattern and disease activity |
| Q33388877 | Anti-neutrophil cytoplasmic antibodies and anti-endothelial cell antibodies |
| Q51764280 | Anti-neutrophil cytoplasmic antibodies and their clinical significance. |
| Q27486368 | Anti-neutrophil cytoplasmic antibodies and vasculitis |
| Q69046267 | Anti-neutrophil cytoplasmic antibodies associated with atrial myxoma |
| Q73867447 | Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease with special attention for IgA-class antibodies |
| Q40978265 | Anti-neutrophil cytoplasmic antibodies in primary small vessel vasculitides |
| Q51637403 | Anti-neutrophil cytoplasmic antibodies target sequential functional proteinase 3 epitopes in the sera of patients with Wegener's granulomatosis |
| Q40636649 | Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential |
| Q69927161 | Anti-neutrophil cytoplasmic antibody assay in diagnosis of recurrent subglottic stenosis |
| Q70575943 | Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in children |
| Q72226264 | Anti-neutrophil cytoplasmic auto-antibodies-associated vasculitis with pulmonary and renal involvement |
| Q40559217 | Anti-neutrophil cytoplasmic autoantibodies (ANCA) and vasculitis |
| Q68311004 | Anti-neutrophil cytoplasmic autoantibodies in a child with pauci-immune necrotizing and crescentic glomerulonephritis |
| Q67576497 | Anti-neutrophil cytoplasmic autoantibodies in inflammatory bowel diseases (IBD) |
| Q27473545 | Anti-neutrophil cytoplasmic autoantibodies in patients with symptomatic HIV infection |
| Q33605284 | Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro |
| Q27478432 | Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis |
| Q43908453 | Anti-nuclear, anti-neutrophil cytoplasmic and anti-glomerular basement membrane antibodies in HIV-infected individuals |
| Q28732877 | Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system |
| Q43887874 | Anti-proteinase 3 antibodies (c-ANCA) prime CD14-dependent leukocyte activation |
| Q72769496 | Anti-proteinase 3 antibodies, their characterization and disease associations |
| Q43757754 | Antibodies to cathepsin G in Crohn's disease |
| Q69906887 | Antibodies to neutrophil cytoplasmic antigen in systemic vasculitis |
| Q36200722 | Antibodies to neutrophil cytoplasmic antigens in Wegener's granulomatosis and other conditions. |
| Q67914546 | Antibodies to neutrophil granulocyte myeloperoxidase and elastase: autoimmune responses in glomerulonephritis due to hydralazine treatment |
| Q71601229 | Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells |
| Q39755699 | Antibodies to proteinase 3 prime human oral, lung, and kidney epithelial cells to secrete proinflammatory cytokines upon stimulation with agonists to various Toll-like receptors, NOD1, and NOD2. |
| Q80575984 | Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA) |
| Q59509727 | Anticuerpos anticitoplasma de los neutrófilos en el diagnóstico de la colitis ulcerosa y la enfermedad de Crohn |
| Q74250091 | Anticytokeratins are a potential source of false-positive indirect immunofluorescence assays for C-ANCA |
| Q46374979 | Anticytoplasmic antibodies in Wegener's granulomatosis |
| Q41841296 | Anticytoplasmic autoantibodies in the diagnosis and follow-up of Wegener's granulomatosis |
| Q41185501 | Anticytoplasmic autoantibody test for Wegener's granulomatosis |
| Q45233268 | Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis |
| Q41680451 | Antimyeloperoxidase Antibodies Induce Neutrophil Adherence to Cultured Human Endothelial Cells |
| Q41973264 | Antimyeloperoxidase antibodies in the Churg-Strauss syndrome |
| Q36508772 | Antineutrophil Cytoplasmic Autoantibodies: Disease Associations, Molecular Biology, and Pathophysiology |
| Q68009952 | Antineutrophil antibodies (ANCA) |
| Q72722711 | Antineutrophil cytoplasm antibodies (ANCA) of IgA isotype in adult Henoch-Schönlein purpura |
| Q27477816 | Antineutrophil cytoplasm antibodies and vasculitis |
| Q35624317 | Antineutrophil cytoplasm antibodies in Kawasaki disease |
| Q27477996 | Antineutrophil cytoplasm antibody in crescentic glomerulonephritis |
| Q33617706 | Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease |
| Q33915352 | Antineutrophil cytoplasmic antibodies (ANCA) and systemic vasculitis: update of assays, immunopathogenesis, controversies, and report of a novel de novo ANCA-associated vasculitis after kidney transplantation |
| Q37891185 | Antineutrophil cytoplasmic antibodies (ANCA) and vasculitis |
| Q44663102 | Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis |
| Q71460985 | Antineutrophil cytoplasmic antibodies (ANCA) in rheumatoid arthritis: a prospective study |
| Q36086150 | Antineutrophil cytoplasmic antibodies (ANCA). |
| Q68246752 | Antineutrophil cytoplasmic antibodies and antibodies to myeloperoxidase in rheumatoid arthritis |
| Q43928839 | Antineutrophil cytoplasmic antibodies in Bulgarian patients with rheumatoid arthritis: characterization and clinical associations |
| Q35260781 | Antineutrophil cytoplasmic antibodies in Wegener's granulomatosis |
| Q40952871 | Antineutrophil cytoplasmic antibodies in chronic idiopathic intraocular inflammatory disease |
| Q77609403 | Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features |
| Q34654595 | Antineutrophil cytoplasmic antibodies in scleroderma patients: first report of a case with anti-proteinase 3 antibodies and review of the literature |
| Q71731389 | Antineutrophil cytoplasmic antibodies in systemic sclerosis |
| Q44316844 | Antineutrophil cytoplasmic antibodies induce decreased CD62L expression and enhanced metabolic activity in monocytes |
| Q41987176 | Antineutrophil cytoplasmic antibodies induce reactive oxygen-dependent dysregulation of primed neutrophil apoptosis and clearance by macrophages |
| Q35038822 | Antineutrophil cytoplasmic antibodies testing in a large cohort of unselected greek patients |
| Q36550721 | Antineutrophil cytoplasmic antibodies. |
| Q40998648 | Antineutrophil cytoplasmic antibodies: major autoantigens, pathophysiology, and disease associations |
| Q27472722 | Antineutrophil cytoplasmic antibody and the gastroenterologist |
| Q27473386 | Antineutrophil cytoplasmic antibody and vasculitis: much more than a disease marker |
| Q46909027 | Antineutrophil cytoplasmic antibody in uveitis and scleritis |
| Q37381624 | Antineutrophil cytoplasmic antibody--a useful serological marker for vasculitis |
| Q39199986 | Antineutrophil cytoplasmic antibody-associated glomerulonephritis with immunoglobulin deposition |
| Q37592578 | Antineutrophil cytoplasmic autoantibodies and associated diseases: a review |
| Q53653899 | Antineutrophil cytoplasmic autoantibodies in patients with systemic lupus erythematosus recognize a novel 69 kDa target antigen of neutrophil granules. |
| Q36377451 | Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming |
| Q36704862 | Antineutrophil cytoplasmic autoantibodies: Immunobiological aspects |
| Q37051208 | Antineutrophil cytoplasmic autoantibodies: how should the biologist manage them? |
| Q42622575 | Antineutrophil cytoplasmic autoantibody-associated diseases: a pathologist's perspective |
| Q67937958 | Antineutrophil cytoplasmic autoantibody-associated diseases: a rheumatologist's perspective |
| Q27478353 | Apoptosis of endothelial cells induced by the neutrophil serine proteases proteinase 3 and elastase |
| Q44606560 | Apoptosis-induced proteinase 3 membrane expression is independent from degranulation |
| Q33640438 | Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)? |
| Q34449107 | Are antineutrophil cytoplasmic antibodies pathogenic? Experimental approaches to understand the antineutrophil cytoplasmic antibody phenomenon |
| Q34449112 | Are antineutrophil cytoplasmic antibody-associated vasculitides pauci-immune? |
| Q38853148 | Are the 1990 American College of Rheumatology vasculitis classification criteria still valid? |
| Q27478351 | Arteritis in a novel congenic strain of mice derived from MRL/Lpr lupus mice: genetic dissociation from glomerulonephritis and limited autoantibody production |
| Q36132380 | Aspects of science in Scandinavian rheumatology--the making of a specialty |
| Q27485913 | Assessment of disease activity in systemic vasculitis |
| Q67518037 | Association of IgM with IgG ANCA in patients presenting with pulmonary hemorrhage |
| Q33567489 | Association of Wegener's granulomatosis with HLA antigens and other genetic markers |
| Q42137237 | Association of alkaline phosphatase with an autoantigen recognised by circulating anti-neutrophil antibodies in systemic vasculitis |
| Q74459185 | Australasian orbital and adnexal Wegener's granulomatosis |
| Q36061831 | Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2. |
| Q68187926 | Autoantibodies against cytoplasmic structures of neutrophil granulocytes in Wegener's granulomatosis |
| Q37873413 | Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis |
| Q68476578 | Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus |
| Q24804699 | Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease |
| Q74529379 | Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview |
| Q71729336 | Autoantibodies and target antigens in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides |
| Q38657160 | Autoantibodies and their Judicious Use in Pediatric Rheumatology Practice |
| Q84675165 | Autoantibodies in ANCA-associated Vasculitis |
| Q27489093 | Autoantibodies in primary sclerosing cholangitis |
| Q24804645 | Autoantibodies in vasculitis |
| Q68497429 | Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis |
| Q68606541 | Autoantibodies to endothelial cells and neutrophil cytoplasmic antigens in systemic vasculitis |
| Q41459036 | Autoantibodies to lactoferrin and histone in systemic vasculitis identified by anti-myeloperoxidase solid phase assays |
| Q67485743 | Autoantibodies to leucocyte antigens in hydralazine‐associated nephritis |
| Q46045653 | Autoantibodies to native myeloperoxidase in patients with pulmonary hemorrhage and acute renal failure |
| Q36490242 | Autoimmune hepatitis as a unique form of an autoimmune liver disease: immunological aspects and clinical overview |
| Q24644140 | Autoimmune liver serology: current diagnostic and clinical challenges |
| Q41605562 | Autoimmune reactivity in inflammatory bowel disease. |
| Q37951576 | Autoimmunity and the pathogenesis of glomerulonephritis |
| Q38620448 | Autoimmunity in rapidly progressive glomerulonephritis |
| Q36907743 | Automated interpretation of ANCA patterns - a new approach in the serology of ANCA-associated vasculitis. |
| Q71018500 | Azurocidin is a novel antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in systemic vasculitis |
| Q38207938 | B cell-mediated pathogenesis of ANCA-mediated vasculitis |
| Q37049182 | B-cell depletion in Wegener's granulomatosis. |
| Q40564213 | Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis |
| Q27485164 | Bench-to-bedside review: Pulmonary–renal syndromes – an update for the intensivist |
| Q57611404 | Binding of proteinase 3 and myeloperoxidase to endothelial cells: ANCA-mediated endothelial damage through ADCC? |
| Q40839782 | Biomarkers Predict Relapse in Granulomatosis with Polyangiitis |
| Q28080053 | Biomarkers to guide clinical therapeutics in rheumatology? |
| Q87305316 | C-ANCA Associated Vasculitis Presenting as Isolated Leptomeningeal Enhancement |
| Q41036367 | Capture-ELISA based on recombinant PR3 is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR3 immunecomplexes |
| Q74497730 | Catalase and alpha-enolase: two novel granulocyte autoantigens in inflammatory bowel disease (IBD) |
| Q39545142 | Changes in the orbital tissues and muscles dysthyroid ophthalmopathy |
| Q37460636 | Changes in urinary metabolomic profile during relapsing renal vasculitis |
| Q73264886 | Characterization of monoclonal antibodies to proteinase 3 (PR3) as candidate tools for epitope mapping of human anti-PR3 autoantibodies |
| Q69367784 | Circulating anti-elastase in systemic lupus erythematosus |
| Q69898359 | Circulating anti-neutrophil antibodies in systemic vasculitis |
| Q41454218 | Classification and management of necrotising vasculitides |
| Q38663854 | Classification and pathogenesis of arteritis in children |
| Q38160767 | Classification of ANCA-associated vasculitis |
| Q36208055 | Classification of the vasculitides: are they clinically useful? |
| Q38389842 | Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. |
| Q41197824 | Classification, pathogenesis, and treatment of systemic vasculitis |
| Q51563811 | Clinic manifestations in granulomatosis with polyangiitis. |
| Q27473540 | Clinical and pathological classification of ANCA-associated vasculitis: what are the controversies? |
| Q37592015 | Clinical and pathophysiological significance of anti-neutrophil cytoplasmic autoantibodies in vasculitis syndromes |
| Q37626123 | Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology. |
| Q38382986 | Clinical aspects of indirect immunofluorescence for autoimmune diseases |
| Q34395162 | Clinical aspects of primary vasculitis |
| Q48027607 | Clinical course and symptomatic prediagnostic period of patients with Wegener's granulomatosis and microscopic polyangiitis |
| Q44919018 | Clinical features of bilateral progressive hearing loss associated with myeloperoxidase-antineutrophil cytoplasmic antibody |
| Q40270805 | Clinical features of patients with anti-neutrophil cytoplasmic autoantibodies targeting native myeloperoxidase antigen |
| Q41843290 | Clinical immunology |
| Q34395174 | Clinical management and treatment of vasculitis |
| Q80505002 | Clinical relevance of anti-PR3 capture ELISA in diagnosing Wegener's granulomatosis |
| Q33604676 | Clinical relevance of testing for antineutrophil cytoplasm antibodies (ANCA) with a standard indirect immunofluorescence ANCA test in patients with upper or lower respiratory tract symptoms |
| Q73876496 | Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases |
| Q72881678 | Clinical significance of antineutrophil cytoplasmic autoantibodies with specificity for lactoferrin in renal diseases |
| Q27477923 | Clinical spectrum associated with positive ANCA titres in 94 consecutive patients: is there a relation with PR-3 negative c-ANCA and hypergammaglobulinaemia? |
| Q39400323 | Clinical trial for Japanese patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-associated vasculitis: the JMAAV study |
| Q33726350 | Clinical utility of testing for antineutrophil cytoplasmic antibodies. |
| Q34109070 | Clinical value of antineutrophil cytoplasmic antibodies |
| Q37210626 | Comparative evaluation of unfixed and fixed human neutrophils for determination of antineutrophil cytoplasmic antibodies by indirect immunofluorescence |
| Q73165903 | Comparison of Dutch and US patients' perceptions of the effects of Wegener's granulomatosis on health, function, income, and interpersonal relationships: comment on the article by Hoffman et al |
| Q74058927 | Comparison of eight commercial kits for quantitation of antineutrophil cytoplasmic antibodies (ANCA) |
| Q67701101 | Comparison of immunofluorescence and an immunohistochemical technique for the detection of perinuclear anti-neutrophil cytoplasmic antibody |
| Q42152357 | Complement receptor Mac-1 is an adaptor for NB1 (CD177)-mediated PR3-ANCA neutrophil activation |
| Q72737329 | Computed tomography of the lung in Wegener's granulomatosis |
| Q36366830 | Constitutive expression of bcl-2 in B cells causes a lethal form of lupuslike autoimmune disease after induction of neonatal tolerance to H-2b alloantigens |
| Q38543360 | Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients? |
| Q43781926 | Correlation between the levels of circulating adhesion molecules and PR3-ANCA in Wegener's granulomatosis |
| Q27486517 | CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis |
| Q38206402 | Critical appraisal of classification criteria for vasculitides |
| Q34422614 | Current and emerging techniques for ANCA detection in vasculitis |
| Q38228853 | Current concepts of the lethal midline granuloma syndrome |
| Q35129462 | Cutaneous Wegener's granulomatosis: a variant or atypical localized form? |
| Q72196972 | Cutaneous Wegener's granulomatosis: clinical, histopathologic, and immunopathologic features of thirty patients |
| Q73624311 | Cutaneous manifestations of Churg-Strauss syndrome: a clinicopathologic correlation |
| Q53612047 | Cutaneous sarcoid-like granulomas with alveolar hemorrhage and c-ANCA PR-3. |
| Q40375129 | Cutaneous vasculitis and cutaneous vasculopathies |
| Q37579770 | Cutaneous vasculitis: approach to diagnosis and systemic associations |
| Q72179302 | Cytotoxic effects of antibodies to proteinase 3 (C-ANCA) on human endothelial cells |
| Q71517619 | Decreased frequency of HLA-DR13DR6 in Wegener's granulomatosis |
| Q33873640 | Decreased numbers of blood dendritic cells and defective function of regulatory T cells in antineutrophil cytoplasmic antibody-associated vasculitis |
| Q80089538 | Defensins- and cathepsin G-ANCA in systemic lupus erythematosus |
| Q40874605 | Descriptive definition and historic aspects of sarcoidosis |
| Q74241511 | Detection by flow cytometry of antibodies against surface and intracellular granulocyte antigens |
| Q58287681 | Detection of Anti-neutrophil Cytoplasmic Antibodies (ANCA) Using the Immunoperoxidase Method |
| Q27473452 | Detection of anti-myeloperoxidase and anti-elastase antibodies in vasculitides and infections |
| Q33564054 | Detection of antineutrophil cytoplasmic antibody in a patient with L-tryptophan induced eosinophilia-myalgia syndrome |
| Q68309071 | Detection of autoantibodies against myeloid lysosomal enzymes: A useful adjunct to classification of patients with biopsy-proven necrotizing arteritis |
| Q35549984 | Detection of immune deposits in skin lesions of patients with Wegener's granulomatosis |
| Q33712321 | Detection rate and antigenic specificities of antineutrophil cytoplasmic antibodies in chinese patients with clinically suspected vasculitis |
| Q67486375 | Determination of anti-neutrophil cytoplasm antibodies (ANCA) specificity by immunofluorescence on chronic myelocytic leukemia cells |
| Q37939577 | Diagnosis and management of glomerulonephritis and vasculitis presenting as acute renal failure |
| Q38033433 | Diagnosis and management of pulmonary vasculitis |
| Q33648618 | Diagnosis and management of systemic Wegener's granulomatosis presenting with anterior ocular inflammatory disease |
| Q58294077 | Diagnostic Specificity of Anti-neutrophil Cytoplasmic Antibodies (ANCA) inOtorhinolaryngologicalDiseases |
| Q67756754 | Diagnostic Value and Limitations of Orbital Biopsy in Wegener's Granutomatosis |
| Q67756759 | Diagnostic Value of Anti-neutrophil Cytoplasmic Antibodies in Scleritis Associated with Wegener's Granulomatosis |
| Q34187942 | Diagnostic and pathogenetic role of antineutrophil cytoplasmic autoantibodies |
| Q68308228 | Diagnostic criteria of periarteritis nodosa |
| Q39607034 | Diagnostic value of classical and atypical antineutrophil cytoplasmic antibody (ANCA) immunofluorescence patterns |
| Q28362587 | Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy |
| Q51015211 | Disease activity and autoantibodies to endothelial cells in patients with Wegener's granulomatosis. |
| Q72432507 | Disease relapse in patients with ocular manifestations of Wegener granulomatosis |
| Q27473451 | Diverse target antigens recognized by circulating antibodies in anti-neutrophil cytoplasm antibody-associated renal vasculitides |
| Q44805797 | Diversity of PR3-ANCA epitope specificity in Wegener's granulomatosis. Analysis using the biosensor technology |
| Q41705365 | Does analysis of the antigenic specificities of anti-neutrophil cytoplasmic antibodies contribute to their clinical significance in the inflammatory bowel diseases? |
| Q37240820 | ELISA is the superior method for detecting antineutrophil cytoplasmic antibodies in the diagnosis of systemic necrotising vasculitis |
| Q50556066 | Ear involvement in Wegener's granulomatosis. |
| Q78197593 | Early vasculitis in the mercuric chloride induced Brown Norway rat model is neutrophil independent |
| Q37225567 | Effect of diagnostic delay on disease severity and outcome in glomerulonephritis caused by anti-neutrophil cytoplasmic antibodies |
| Q37263446 | Effect of proctocolectomy on serum antineutrophil cytoplasmic antibodies in patients with chronic ulcerative colitis |
| Q93161825 | Effector and regulatory B cells in immune-mediated kidney disease |
| Q84277634 | Elevated neutrophil membrane expression of proteinase 3 is dependent upon CD177 expression |
| Q33701603 | Endothelial Alterations in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Potential Effect of Monocyte Interaction. |
| Q41291859 | Endothelial cells and renal epithelial cells do not express the Wegener's autoantigen, proteinase 3. |
| Q36200937 | Endothelium-neutrophil interactions in ANCA-associated diseases |
| Q38533019 | Epigenetics and Vasculitis: a Comprehensive Review |
| Q27478112 | Epitope mapping of anti-PR3 antibodies using chimeric human/mouse PR3 recombinant proteins |
| Q27473530 | Epitope mapping of anti-proteinase 3 and anti-myeloperoxidase antibodies |
| Q53316606 | Exceptional matters. |
| Q27488322 | Experimental Autoimmune Vasculitis |
| Q27468849 | Experimentally-induced anti-myeloperoxidase vasculitis does not require properdin, MASP-2 or bone marrow-derived C5 |
| Q40859078 | Expression of cytokines and growth factors in human glomerulonephritides |
| Q40709360 | Expression of recombinant proteinase 3, the autoantigen in Wegener's granulomatosis, in insect cells |
| Q59139072 | Extensive Endoscopic Image-Guided Sinus Surgery Decreases BPI-ANCA in Patients with Cystic Fibrosis |
| Q39993490 | Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. |
| Q44998018 | Fcgamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse |
| Q48565963 | Fokko Johannes van der Woude, 1953-2006. |
| Q37804609 | FoxP3+ CD4+ T cells in systemic autoimmune diseases: the delicate balance between true regulatory T cells and effector Th-17 cells |
| Q35872951 | Fundamental and clinical aspects of anti neutrophil cytoplasmic antibodies (ANCA). |
| Q27490156 | Gene expression in systemic lupus erythematosus: Bone marrow analysis differentiates active from inactive disease and reveals apoptosis and granulopoiesis signatures |
| Q47106268 | Gene silencing and a novel monoallelic expression pattern in distinct CD177 neutrophil subsets |
| Q36682502 | Glomerulonephritis associated with antibodies to neutrophil cytoplasm and glomerular basement membrane |
| Q73738667 | Granulocyte-macrophage colony-stimulating factor (GM-CSF) but not granulocyte colony-stimulating factor (G-CSF) induces plasma membrane expression of proteinase 3 (PR3) on neutrophils in vitro |
| Q26748200 | Granulomatosis with polyangiitis (Wegener's disease): An updated review of ocular disease manifestations |
| Q37979678 | Granulomatosis with polyangiitis in childhood |
| Q33618038 | Granulomatous gastritis in Wegener's disease: differentiation from Crohn's disease supported by a positive test for antineutrophil antibodies |
| Q41839075 | HLA antigen frequencies and Wegener's granulomatosis |
| Q67541886 | HLA class II specificities in vasculitis with antibodies to neutrophil cytoplasmic antigens |
| Q35563345 | Head and neck manifestations of Wegener's granulomatosis |
| Q35508238 | Heterogeneity of anti-PR3 associated disease in Hong Kong |
| Q77083776 | Histological findings in biopsies from patients with cytoplasmic-antineutrophil cytoplasmic antibody (cANCA)-positive Wegener's granulomatosis |
| Q43228191 | Historical milestones in renal pathology |
| Q53364451 | Historical perspective on the classification of vasculitis. |
| Q38031925 | How anti-neutrophil cytoplasmic autoantibodies activate neutrophils |
| Q67937950 | How are antineutrophil cytoplasmic autoantibodies detected? |
| Q44029848 | Human proteinase 3 can inhibits LPS-mediated TNF-alpha production through CD14 degradation: lack of influence of antineutrophil cytoplasmic antibodies |
| Q36884782 | IBD serological panels: facts and perspectives |
| Q45645296 | Identification of an autoantibody to vascular endothelial cell-specific antigens in patients with systemic vasculitis |
| Q27478109 | IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis |
| Q70667738 | IgG and IgA classes of anti-neutrophil cytoplasmic autoantibodies in a 13-year-old girl with recurrent Henoch-Schonlein purpura |
| Q68272887 | IgG subclass distribution and relative functional affinity of anti-myeloperoxidase antibodies in systemic vasculitis at presentation and during follow-up |
| Q70176998 | IgG subclass distribution of autoantibodies to neutrophil cytoplasmic antigens in systemic vasculitis |
| Q97541954 | Imaging flow cytometry methods for quantitative analysis of label-free crystalline silica particle interactions with immune cells |
| Q37988856 | Immune-complex deposits in "pauci-immune" glomerulonephritis: a case report and brief review of recent literature |
| Q71730880 | Immunization with anti-neutrophil cytoplasmic antibody (ANCA) induces the production of mouse ANCA and perivascular lymphocyte infiltration |
| Q42173432 | Immunofluorescent patterns produced by antineutrophil cytoplasmic antibodies (ANCA) vary depending on neutrophil substrate and conjugate |
| Q52180350 | Immunologic tests in rheumatology. |
| Q38141760 | Immunological features of diffuse connective tissue diseases |
| Q39675170 | Immunopathogenesis of crescentic glomerulonephritis and lung purpura |
| Q34395169 | Immunopathological aspects of systemic vasculitis |
| Q47594206 | Immunoregulatory defects of V alpha 24V+ beta 11+ NKT cells in development of Wegener's granulomatosis and relapsing polychondritis. |
| Q46673827 | Immunosuppressive therapy and clinical evolution in forty-nine patients with antineutrophil cytoplasmic antibody-associated glomerulonephritis |
| Q73936273 | Immunosuppressive therapy with cyclophosphamide pulse doses in Wegener's granulomatosis |
| Q54637269 | Impaired granulocyte oxidative burst and decreased expression of leucocyte adhesion molecule-1 (LAM-1) in patients with Wegener's granulomatosis. |
| Q35212086 | Improved prognosis in Norwegian patients with glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies |
| Q70616889 | In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis |
| Q73310113 | In vitro T lymphocyte responses to proteinase 3 (PR3) and linear peptides of PR3 in patients with Wegener's granulomatosis (WG) |
| Q44068966 | In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase |
| Q33767020 | Increased frequency of circulating IL-21 producing Th-cells in patients with granulomatosis with polyangiitis (GPA). |
| Q27477862 | Indirect immunofluorescence (IIF) of normal washed peripheral blood cells to demonstrate antineutrophil cytoplasmic antibodies (ANCA) |
| Q71293437 | Indirect immunofluorescence study of the cornea and the conjunctiva in a xenogeneic system: analysis of humoral reactivity in patients with Wegener's granulomatosis |
| Q40464546 | Inhibition of proteinase 3 by ANCA and its correlation with disease activity in Wegener's granulomatosis |
| Q44116012 | Interference of PR3-ANCA with the enzymatic activity of PR3: differences in patients during active disease or remission of Wegener's granulomatosis |
| Q67599006 | Interference of Wegener's granulomatosis autoantibodies with neutrophil Proteinase 3 activity |
| Q33357114 | Interleukin-8 and polymorphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood |
| Q27473448 | Invasive amoebiasis is associated with the development of anti-neutrophil cytoplasmic antibody |
| Q44655263 | Involvement of Fcγ receptors andβ2 integrins in neutrophil activation by anti-proteinase-3 or anti-myeloperoxidase antibodies |
| Q47586571 | Is it possible to offer evidence-based treatment for systemic vasculitis? |
| Q41529206 | Laboratory findings in the vasculitides |
| Q37634640 | Laboratory investigation in the diagnosis of vasculitis |
| Q27469322 | Lack of effect of antineutrophil cytoplasmic antibodies associated with ulcerative colitis on superoxide anion production from neutrophils |
| Q40535191 | Large pyoderma gangrenosum-like ulcers: a rare presentation of granulomatosis with polyangiitis. |
| Q72138964 | Lesions of the respiratory tract associated with the finding of anti-neutrophil cytoplasmic autoantibodies with a perinuclear staining pattern |
| Q85185616 | Lest we forget: statement by the German rheumatology society (DGRh) on the national socialist crimes against Jewish colleagues |
| Q88391689 | Letter to the Editor: "Risk of venous thromboembolism among patients with vasculitis: a systematic review and meta-analysis" |
| Q34449131 | Leukocyte-endothelial interactions in antineutrophil cytoplasmic antibody-associated systemic vasculitis |
| Q36972471 | Leukocytes in glomerular injury |
| Q38765101 | Limbal allergic granulomatosis |
| Q36865417 | Lingual infarction in Wegener's Granulomatosis: a case report and review of the literature |
| Q37928540 | Localised Wegener's granulomatosis--a difficult and delayed diagnosis. Clinical report and literature review |
| Q52915030 | Long-term treatment results and the immunoglobulin G subclass distribution patterns of proteinase-3-antineutrophil cytoplasm antibody (ANCA) and myeloperoxidase-ANCA in ANCA-associated vasculitis. |
| Q35877521 | Low Serum Alpha-Antitrypsin Associated with Anti-PR-3 ANCA in Autistic Children with GI Disease |
| Q38327634 | Maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: who needs what and for how long? |
| Q40320143 | Make the grade for Wegener's granulomatosis after kidney transplantation |
| Q38670973 | Managing rheumatic and musculoskeletal diseases - past, present and future |
| Q40653683 | Mechanisms of endothelial cell injury in vasculitis |
| Q90320547 | Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation |
| Q34395155 | Methods for the detection of anti-neutrophil cytoplasmic antibodies. Recommendations for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results |
| Q40379203 | Microscopic polyangiitis initiated with liver dysfunction, calf pain and fever of unknown origin. |
| Q36723568 | Microscopic polyarteritis: clinical features and treatment |
| Q36788186 | Molecular characteristics of anti-self antibody fragments against neutrophil cytoplasmic antigens from human V gene phage display libraries |
| Q27489747 | Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis |
| Q35923750 | Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis. |
| Q55401446 | Monocyte Chemoattractant Protein-1 in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis: Biomarker Potential and Association with Polymorphisms in the MCP-1 and the CC Chemokine Receptor-2 Gene. |
| Q48763188 | Multiple cerebral infarcts with a few vasculitic lesions in the chronic stage of cerebral amyloid angiopathy-related inflammation |
| Q40898688 | Myelodysplasia, vasculitis and anti-neutrophil cytoplasm antibodies. |
| Q42122199 | Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis |
| Q71116135 | Nasal biopsy in the early diagnosis of Wegener's (pathergic) granulomatosis. Significance of palisading granuloma and leukocytoclastic vasculitis |
| Q47594489 | Necroptosis controls NET generation and mediates complement activation, endothelial damage, and autoimmune vasculitis |
| Q50525159 | Negative ANCA in Wegener's granulomatosis. |
| Q33563096 | Negative antineutrophil cytoplasmic antibodies in Behçet's disease |
| Q42973858 | Nephrology, dialysis and transplantation |
| Q24679901 | Neurology of the vasculitides and connective tissue diseases |
| Q38936537 | Neutral serine proteases of neutrophils |
| Q38815813 | Neutrophil Extracellular Traps Contain Selected Antigens of Anti-Neutrophil Cytoplasmic Antibodies |
| Q42943784 | Neutrophil activation by anti-proteinase 3 antibodies in Wegener's granulomatosis: role of exogenous arachidonic acid and leukotriene B4 generation |
| Q46826630 | Neutrophil activation in anti-proteinase 3-positive vasculitis--a prospective study |
| Q72005028 | Neutrophil activation in vitro and in vivo in Wegener's granulomatosis |
| Q70642205 | Neutrophil alloantibodies react with cytoplasmic antigens: a possible cause of false-positive indirect immunofluorescence assays for antibodies to neutrophil cytoplasmic antigens |
| Q71730870 | Neutrophil and recombinant myeloperoxidase as antigens in ANCA positive systemic vasculitis |
| Q37532293 | Neutrophil autoantibodies as disease markers for ulcerative colitis |
| Q59882681 | Neutrophil autoantibodies in ulcerative colitis: Familial aggregation and genetic heterogeneity |
| Q72756357 | Neutrophil cytoplasmic autoantibodies after liver transplantation in patients with primary sclerosing cholangitis |
| Q35172206 | Neutrophil-specific autoantibodies in chronic inflammatory bowel diseases |
| Q90415245 | New concepts in ANCA detection and disease classification in small vessel vasculitis: the role of ANCA antigen specificity |
| Q36834892 | New horizons in renal vasculitis |
| Q38883608 | Next-Generation Autoantibody Testing by Combination of Screening and Confirmation-the CytoBead® Technology. |
| Q27480493 | No association between neutrophil FcgammaRIIa allelic polymorphism and anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis |
| Q37859104 | Nomenclature and classification of vasculitis - update on the ACR/EULAR diagnosis and classification of vasculitis study (DCVAS). |
| Q43723757 | Novel SNPs in the CD18 gene validate the association with MPO-ANCA+ vasculitis |
| Q27000411 | Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies |
| Q69433347 | Opportunistic infection and antineutrophil cytoplasm antibodies in Wegener's granulomatosis |
| Q51714926 | Orbital involvement as the first manifestation in classic Wegener's granulomatosis. |
| Q37778133 | Outcome Measures in ANCA-associated Vasculitis |
| Q35094863 | Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study |
| Q74324314 | Outcome of antineutrophil cytoplasmic autoantibodies-positive glomerulonephritis and vasculitis in children: a single-center experience |
| Q33997788 | P-ANCA-positive Wegener's granulomatosis presenting with hypertrophic pachymeningitis and multiple cranial neuropathies: case report and review of literature |
| Q27489023 | PR3-ANCA in Wegener's granulomatosis prime human mononuclear cells for enhanced activation via TLRs and NOD1/2 |
| Q59509743 | Papel de los anticuerpos anticitoplasma de los neutrófilos (ANCA) y anti-Saccharomyces cerevisiae (ASCA) en la enfermedad inflamatoria intestinal |
| Q44895920 | Parotid gland involvement as a presenting feature of Wegener's granulomatosis |
| Q33843581 | Pathogenesis of ANCA-associated systemic vasculitis |
| Q37845187 | Pathogenesis of ANCA-associated vasculitis, an update |
| Q44570553 | Pathogenesis of ANCA-positive vasculitides: recent advances |
| Q45160848 | Pathogenesis of primary systemic vasculitides (I): ANCA-positive vasculitides |
| Q41333535 | Pathogenesis of vasculitis syndromes |
| Q36535223 | Pathogenic role and clinical relevance of antineutrophil cytoplasmic antibodies in vasculitides |
| Q37803098 | Pathophysiological importance of antineutrophil antibodies in vasculitis |
| Q82698398 | Patients with Wegener's granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells |
| Q45917648 | Pauci-immune glomerulonephritis: does negativity of anti-neutrophilic cytoplasmic antibodies matters? |
| Q74600527 | Pauci-immune rapidly progressive glomerulonephritis after nephrectomy in a renal donor |
| Q27473525 | Peripheral blood T lymphocytes in systemic vasculitis: increased T cell receptor V beta 2 gene usage in microscopic polyarteritis |
| Q43243973 | Phosphoinositol 3-kinase-gamma mediates antineutrophil cytoplasmic autoantibody-induced glomerulonephritis |
| Q36717473 | Pitfalls in the diagnosis of Wegener's granulomatosis on fine needle aspiration cytology |
| Q38891121 | Pitfalls with anti-neutrophil cytoplasmic antibodies (ANCA). |
| Q28298876 | Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies |
| Q40671350 | Pleural effusion as a presenting manifestation of giant cell arteritis |
| Q28336000 | Pneumorenal syndrome induced by d-penicillamine: Goodpasture's syndrome or microscopic polyarteritis? |
| Q68314432 | Polyangiitis overlap syndrome with features of Wegener's granulomatosis and Panarteriitis nodosa |
| Q74714031 | Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome |
| Q79136036 | Poor renal outcome of antineutrophil cytoplasmic antibody negative Pauci-immune glomerulonephritis in Taiwanese |
| Q40041740 | Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. |
| Q34730043 | Prediction of response to treatment by gene expression profiling of peripheral blood in patients with microscopic polyangiitis |
| Q44821403 | Predominance of IgGl and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders |
| Q43612312 | Pregnancy in women diagnosed with antineutrophil cytoplasmic antibody-associated vasculitis: outcome for the mother and the child |
| Q38232599 | Presentation and initial assessment of ENT problems in patients with granulomatosis with polyangiitis (Wegener's). |
| Q45759750 | Presenting features in Wegener's granulomatosis |
| Q69174313 | Proceedings of the British Thoracic Society. 1986 winter meeting. 11-12 December 1986, London. Abstracts |
| Q41592250 | Production of human monoclonal antibodies to myeloperoxidase |
| Q56982101 | Progredientes Nierenversagen mit Hautulkus und Nasenwurzeltumor |
| Q69967479 | Progressive multifocal leukoencephalopathy in Wegener's granulomatosis in relation to therapy with cyclosporin A |
| Q69900045 | Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis |
| Q27480696 | Proteinase 3 and dihydrolipoamide dehydrogenase (E3) are major autoantigens in hepatitis C virus (HCV) infection |
| Q24337938 | Proteinase 3, the Wegener autoantigen, is externalized during neutrophil apoptosis: evidence for a functional association with phospholipid scramblase 1 and interference with macrophage phagocytosis |
| Q35831098 | Proteinase 3, the target antigen of anticytoplasmic antibodies circulating in Wegener's granulomatosis. Immunolocalization in normal and pathologic tissues |
| Q36104863 | Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis |
| Q43768172 | Proteinase-3 (PR-3): a polymorphonuclear leukocyte serine proteinase |
| Q71917546 | Proteolysis of classic anti-neutrophil cytoplasmic autoantibodies (C-ANCA) by neutrophil proteinase 3 |
| Q54776673 | Pulmonary fibrosis and other clinical manifestations of small vessel vasculitis in a family with seropositive juvenile rheumatoid arthritis. |
| Q37939552 | Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients |
| Q37448756 | Pulmonary granulomatosis and angiitis |
| Q37232105 | Pulmonary hemorrhage and necrotizing glomerulonephritis without glomerular immune deposits: report of two cases |
| Q27477901 | Pulmonary vasculitis |
| Q77903314 | Pulmonary vasculitis |
| Q79181944 | Rapidly progressive glomerulonephritis:classification, pathogenesis and clinical management |
| Q27477903 | Rare diseases bullet 11: Churg-Strauss syndrome |
| Q27477902 | Rare diseases.3: Wegener's granulomatosis |
| Q43010830 | Rational requesting or rationing testing? |
| Q40680205 | Rats and mice immunised with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes |
| Q51542464 | Re-evaluation of 129 patients with systemic necrotizing vasculitides by using classification algorithm according to consensus methodology. |
| Q26751357 | Recent advances in anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Q64980226 | Recent advances in understanding of the pathogenesis of ANCA-associated vasculitis. |
| Q42046372 | Recombinant Protein to Analyze Autoantibodies to Proteinase 3 in Systemic Vasculitis |
| Q73875904 | Recombinant proteinase 3 (Wegener's antigen) expressed in Pichia pastoris is functionally active and is recognized by patient sera |
| Q40848895 | Recombinant proteinase 3 produced in different expression systems: recognition by anti-PR3 antibodies |
| Q41323452 | Recurrence of immunoglobulin A nephropathy with immunoglobulin A antineutrophil cytoplasmic antibodies following renal transplantation |
| Q33337715 | Redistribution of myeloperoxidase and elastase in human neutrophil granulocytes |
| Q43924598 | Relationship between anti-neutrophil cytoplasmic antibody determined with conventional binding and the capture assay, and long-term clinical course in vasculitis |
| Q72920731 | Relevance of classic anti-neutrophil cytoplasmic autoantibody (C-ANCA)-mediated inhibition of proteinase 3-alpha 1-antitrypsin complexation to disease activity in Wegener's granulomatosis |
| Q68591107 | Renal biopsy |
| Q39611435 | Renal disease and vasculitis |
| Q41519653 | Renal involvement in primary vasculitides |
| Q42559282 | Renal micropolyarteritis |
| Q36956903 | Renal transplantation in the ANCA-associated vasculitides. |
| Q68515108 | Respiratory diseases |
| Q38829722 | Review: Neutrophils as Invigorated Targets in Rheumatic Diseases |
| Q64055590 | Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series |
| Q36424005 | Role of gingival manifestation in diagnosis of granulomatosis with polyangiitis (Wegener's granulomatosis) |
| Q68891626 | Role of testing for anticytoplasmic autoantibodies in the differential diagnosis of scleritis and orbital pseudotumor |
| Q73251294 | Rupture of a hepatic artery aneurysm caused by Wegener's granulomatosis |
| Q68789629 | Salivary gland involvement in Wegener's granulomatosis |
| Q44021011 | Scleritis and Wegener's granulomatosis in children. |
| Q72611650 | Screening for anti-neutrophil cytoplasmic antibodies (ANCA): is indirect immunofluorescence the method of choice? |
| Q44899131 | Selective killing of B-cell hybridomas targeting proteinase 3, Wegener's autoantigen |
| Q77769303 | Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis |
| Q46106079 | Serodiagnosis of Wegener's granulomatosis: pathobiologic and clinical implications |
| Q40733320 | Serologic tests for connective tissue diseases and the primary vasculitides. |
| Q47144294 | Serum 25-hydroxyvitamin D levels in patients with Granulomatosis with Polyangiitis: association with respiratory infection |
| Q73523422 | Serum autoantibodies in patients with primary sclerosing cholangitis |
| Q69109247 | Serum cytokine changes in systemic vasculitis |
| Q77122611 | Serum levels of soluble adhesion molecules ICAM-1, VCAM-1 and E-selectin in patients with Wegener's granulomatosis |
| Q36683541 | Serum soluble interleukin 2 receptor levels in anti-neutrophil cytoplasmic autoantibodies--positive systemic vasculitis |
| Q68820727 | Seventh European Rheumatology Research Workshop. Glasgow, Scotland, March 6-7, 1987. Abstracts |
| Q68562011 | Severe granulomatous giant cell myocarditis in Wegener's granulomatosis |
| Q36032823 | Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study |
| Q37456161 | Shining a LAMP on pauci-immune focal segmental glomerulonephritis |
| Q58004245 | Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's) |
| Q69368723 | Sicca syndrome in patients with Wegener's granulomatosis |
| Q67705022 | Significance and specificity of antibodies to neutrophils detected by western blotting for the serological diagnosis of primary sclerosing cholangitis |
| Q36200644 | Significance of antibodies to cytoplasmic components of neutrophils |
| Q55520810 | Significance of antibodies to cytoplasmic components of neutrophils. |
| Q37189625 | Significance of antineutrophil cytoplasmic antibody in adult patients with Henoch-Schönlein purpura presenting mainly with gastrointestinal symptoms |
| Q71878208 | Significance of myeloperoxidase in rapidly progressive glomerulonephritis |
| Q39535929 | Significantly high regional morbidity of MPO-ANCA-related angitis and/or nephritis with respiratory tract involvement after the 1995 great earthquake in Kobe (Japan). |
| Q39638749 | Simplified method of preparing neutrophil slides to examine antibodies to cytoplasmic antigens |
| Q34199391 | Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA. |
| Q34376606 | Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibodies in patients with ulcerative colitis |
| Q71627913 | Some patients with anti-myeloperoxidase autoantibodies have a C-ANCA pattern |
| Q67962459 | Spontaneous and induced immunoglobulin synthesis and anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis: relation to leukocyte subpopulations in blood and active lesions |
| Q68331741 | Spontaneous course of Wegener's granulomatosis |
| Q46740393 | Spontaneous oroantral fistula |
| Q26776308 | Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives |
| Q24805982 | Staphylococcus aureus and Wegener's granulomatosis |
| Q41009953 | Structure of the azurocidin, proteinase 3, and neutrophil elastase genes. Implications for inflammation and vasculitis |
| Q73875910 | Studies of epitope restriction on myeloperoxidase (MPO), an important antigen in systemic vasculitis |
| Q33450918 | Studies on anti-granulocyte and anti-platelet antibodies in patients with systemic sclerosis. Chemotaxis, phagocytosis and opsonized effect of PSS sera on normal granulocytes |
| Q41959438 | Subarachnoid haemorrhage in Wegener's granulomatosis, with negative four vessel angiography |
| Q67756764 | Surgical Management of Nasolacrunal Duct Obstruction in Patients with Wegener's Granutomatosis |
| Q67753595 | Systemic vasculitis |
| Q68163908 | Systemic vasculitis in the 1980s--is there an increasing incidence of Wegener's granulomatosis and microscopic polyarteritis? |
| Q48243031 | Systemic vasculitis positive for circulating anti-neutrophil cytoplasmic antibodies and with predominantly neurological presentation |
| Q38774997 | Systemic vasculitis with renal involvement--a review |
| Q54004687 | T cell receptor (TCR) V gene usage in patients with systemic necrotizing vasculitis |
| Q34569292 | Testing for antineutrophil cytoplasmic antibodies |
| Q27469297 | The ANCA test: its clinical relevance |
| Q90211970 | The Diagnostic and Clinical Utility of Autoantibodies in Systemic Vasculitis |
| Q42945203 | The History of ANCA-associated Vasculitis |
| Q36410797 | The Pathogenic Role of Antineutrophil Cytoplasmic Autoantibodies |
| Q71517643 | The PiZ gene of alpha 1-antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis |
| Q37778584 | The Pulmonary Vasculitides |
| Q42024879 | The Third International Workshop on Antineutrophil Cytoplasmic Autoantibodies. Introduction |
| Q72695219 | The absence of anti-neutrophil cytoplasmic antibodies in patients with Henoch-Schönlein purpura |
| Q36707189 | The aetiology and pathogenesis of major systemic vasculitides |
| Q27486181 | The antigenic significance and methods of detection of the anti-neutrophil cytoplasmic autoantibodies (ANCA) |
| Q68259327 | The antihypertensive compounds hydralazine, dihydralazine and cadralazine and their metabolites inhibit myeloperoxidase activity as measured by chemiluminescence |
| Q27469362 | The antineutrophil antibody in uveitis |
| Q40699126 | The arteritides |
| Q36902238 | The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease. |
| Q42058864 | The binding of proteinase 3 antineutrophil cytoplasmic antibodies (PR3-ANCA) varies in different ELISAs. |
| Q39296684 | The changing face of polyarteritis nodosa and necrotizing vasculitis |
| Q52524939 | The clinical and pathologic constellation of Wegener granulomatosis of the orbit. |
| Q27469302 | The clinical utility of ANCA positivity |
| Q27473445 | The current status of neutrophil cytoplasmic antibodies |
| Q72365069 | The diagnosis and management of arteritis |
| Q41197830 | The diagnostic and prognostic significance of ANCA. |
| Q27473538 | The diversity of perinuclear antineutrophil cytoplasmic antibodies (pANCA) antigens |
| Q67975306 | The effect of anti-neutrophil cytoplasm autoantibodies on the signal transduction in human neutrophils |
| Q33495871 | The effect of thymectomy on myasthenia gravis, thrombocytopenia, and granulocytopenia associated with thymoma: report of a case |
| Q68391735 | The eosinophilic variant of Wegener's granulomatosis |
| Q50541003 | The hearing loss in Wegener's granulomatosis: relationship between hearing loss and serum ANCA |
| Q37049174 | The last classification of vasculitis |
| Q71878264 | The mystery of the antineutrophil cytoplasmic antibodies |
| Q36175907 | The necrotising vasculitides |
| Q27027790 | The neutrophil in antineutrophil cytoplasmic autoantibody-associated vasculitis |
| Q54121533 | The pulmonary biopsy in the early diagnosis of Wegener's (pathergic) granulomatosis: A study based on 35 open lung biopsies |
| Q72220415 | The role of cellular immunity in systemic vasculitis |
| Q35002495 | The role of conjunctival biopsy in the diagnosis of granulomatosis with polyangiitis |
| Q53639961 | The sarcoidosis movement and its personalities. |
| Q54382270 | The significance of IgA class of antineutrophil cytoplasmic antibodies (ANCA) in childhood Henoch-Schönlein purpura. |
| Q68162317 | The specificity of anti-neutrophil cytoplasm autoantibodies in systemic vasculitides |
| Q72660201 | The spectrum of disease associated with a positive ANCA |
| Q87954665 | The treatment of ANCA-associated rapidly-progressive glomerulonephritis and Goodpasture syndrome with therapeutic apheresis |
| Q39484864 | The treatment of immune glomerular disease |
| Q50050942 | The usefulness of histopathological examinations of non-renal biopsies in the diagnosis of granulomatosis with polyangiitis. |
| Q27485127 | Theodore E. Woodward Award. Do ANCA cause small vessel vasculitis? |
| Q68162320 | Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides |
| Q33921278 | Transcription of proteinase 3 and related myelopoiesis genes in peripheral blood mononuclear cells of patients with active Wegener's granulomatosis |
| Q44003718 | Tuberculosis of the upper respiratory tract misdiagnosed as Wegener's granulomatosis--an important distinction |
| Q33565477 | Two sisters with ANCA positive vasculitis |
| Q34172675 | Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers |
| Q35812021 | Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis |
| Q64955885 | Unraveling the identity of FoxP3+ regulatory T cells in Granulomatosis with Polyangiitis patients. |
| Q51660911 | Ureteral stenosis as the sole manifestation of Wegener's granulomatosis. |
| Q79319641 | Use of ANCA in diagnosis |
| Q31137060 | Use of immunofluorescence and confocal laser scanning microscopy in identifying rare cases of anti-neutrophil cytoplasmic antibodies (ANCA) showing dual specificities to myeloperoxidase and proteinase3. |
| Q72722713 | Uveitis and anti-neutrophil cytoplasmic antibodies |
| Q35747186 | Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis |
| Q51403741 | Value of a new automated fluorescence immunoassay (EliA) for PR3 and MPO-ANCA in monitoring disease activity in ANCA-associated systemic vasculitis. |
| Q36886158 | Value of opinion by oral physician in diagnosing Wegener's granulomatosis |
| Q46658740 | Vascular damage in Wegener's granulomatosis and microscopic polyarteritis: presence of anti-endothelial cell antibodies and their relation to anti-neutrophil cytoplasm antibodies |
| Q33642739 | Vasculitic peripheral ulcerative keratitis |
| Q73373371 | Vasculitides: classification, clinical aspects and pathology. A review |
| Q41641704 | Vasculitis and the nervous system. Historical perspective and overview |
| Q41529189 | Vasculitis associated with connective tissue disease |
| Q41529201 | Vasculitis by organ systems |
| Q34109091 | Vasculitis from the pediatric perspective |
| Q44517731 | Vasculitis. A practical approach to management |
| Q34990085 | Vasculitis: Wegener granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis, polyarteritis nodosa, and Takayasu arteritis |
| Q38238796 | Vasculitis: an update. |
| Q38284032 | Vasculitis: do we know more to classify better? |
| Q35787303 | Wegener granulomatosis in childhood and adolescence |
| Q28236019 | Wegener's granulomatosis |
| Q33616265 | Wegener's granulomatosis |
| Q74456726 | Wegener's granulomatosis |
| Q67733067 | Wegener's granulomatosis A distinct gingival lesion |
| Q41641740 | Wegener's granulomatosis and ANCA syndromes |
| Q36750657 | Wegener's granulomatosis and autoantibodies to neutrophil antigens |
| Q46138263 | Wegener's granulomatosis and microscopic polyangiitis |
| Q36811431 | Wegener's granulomatosis and the heart |
| Q40380323 | Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils |
| Q37256621 | Wegener's granulomatosis in Finland in 1981-2000: clinical presentation and diagnostic delay |
| Q68676867 | Wegener's granulomatosis in north India. An analysis of eleven patients |
| Q50513576 | Wegener's granulomatosis of the skull base. |
| Q39429423 | Wegener's granulomatosis overlapped with Takayasu arteritis. |
| Q41705016 | Wegener's granulomatosis presenting as a recurrence of chronic otitis media |
| Q34195933 | Wegener's granulomatosis presenting as dilated cardiomyopathy. |
| Q46009518 | Wegener's granulomatosis presenting as granulomatous prostatitis causing urinary retention. |
| Q41076554 | Wegener's granulomatosis presenting as major salivary gland enlargement. |
| Q74316262 | Wegener's granulomatosis presenting as oral lesions: a case report |
| Q68597265 | Wegener's granulomatosis presenting as pulmonary metastases: value of antineutrophil cytoplasmic antibodies in diagnosis |
| Q41142777 | Wegener's granulomatosis simulated by a T cell lymphoma of the lung |
| Q74446867 | Wegener's granulomatosis upper respiratory tract and pulmonary radiographic manifestations in 30 cases with pathogenetic consideration |
| Q35943582 | Wegener's granulomatosis, subglottic stenosis and antineutrophil cytoplasm antibodies |
| Q72291516 | Wegener's granulomatosis. Eyelid and conjunctival manifestations as the presenting feature in two individuals |
| Q50634915 | Wegener's granulomatosis. First case report in Bahrain. |
| Q37929860 | Wegener's granulomatosis. Thoughts and observations of a pathologist |
| Q74231572 | Wegener's granulomatosis: The ocular manifestations revisited |
| Q28393433 | Wegener's granulomatosis: a model of auto-antibodies in mucosal autoimmunity |
| Q36387577 | Wegener's granulomatosis: a rare, chronic and multisystem disease. |
| Q42971464 | Wegener's granulomatosis: anti-proteinase 3 antibodies are potent inductors of human endothelial cell signaling and leakage response |
| Q43863663 | Wegener's granulomatosis: clinical features and prognosis in 37 patients |
| Q69667230 | Wegener's granulomatosis: false positive anti-neutrophil cytoplasmic antibody test |
| Q37976731 | Wegener's granulomatosis: otorhinolaryngological manifestations |
| Q28268942 | Wegener's granulomatosis: the current understanding |
| Q33957306 | What stuff is this! A historical perspective on fibrinoid necrosis |
| Q24791101 | What you should know about PR3-ANCA. An introduction |
| Q42732379 | With complements from ANCA mice |
| Q72170387 | [Allergic angiitis with granulomatosis: the Churg and Strauss syndrome] |
| Q67797534 | [Alveolar hemorrhage, glomerulonephritis and anti-cytoplasmic polynuclear antibodies] |
| Q73173867 | [Antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae mannan antibodies: new biological tools for diagnosis of inflammatory bowel disease] |
| Q70172246 | [Antineutrophil cytoplasmic antibodies: a new diagnostic tool] |
| Q72126234 | [Are antineutrophil cytoplasmic antibodies pathogenic?] |
| Q95811050 | [Classification of ocular surface disease. Part 1] |
| Q81091964 | [Cutaneous vasculitides. A diagnostic approach] |
| Q69740533 | [Favorable course under cotrimoxazole of excavated pneumopathy complicating rapidly progressive glomerulonephritis: Wegener's granulomatosis?] |
| Q50699972 | [Foudroyant course of a therapy resistent Wegener's granulomatosis with negative c-ANCA]. |
| Q84077008 | [Histopathology of systemic vasculitis] |
| Q72126420 | [Kidney and vasculitis] |
| Q82772092 | [Necrotizing granulomatosis with pulmonary, intestinal and renal involvement] |
| Q69372849 | [Renal involvement in necrotizing angiitis] |
| Q72688257 | [Sensitivity and specificity of antineutrophil cytoplasmic antibodies in systemic vasculitis] |
| Q69545448 | [Tracheobronchial sites of Wegener's granulomatosis] |
| Q83593739 | [Vasculitis: histopathology and differential diagnosis] |
Search more.